Avantor® Announces Strong Financial Performance in Third Quarter of 2026

Avantor® Reports Strong Performance in Q3 2026

Avantor, Inc. (NYSE: AVTR), a key player in the provision of essential products and services for the life sciences and advanced technology sectors, showcased noteworthy growth during the third quarter of 2026. Reporting a net sales figure of $1.698 billion, the company achieved a 4.6% increase compared to the same period last year. The impressive performance can be attributed to an organic sales increase of 5.2%, despite facing some adverse currency translation effects.

Highlights of the Quarter

President and CEO Emmanuel Ligner expressed his satisfaction with the results, stating, "We are pleased to see a return to year-over-year growth during the third quarter. This achievement is a testament to the hard work of our team and our focused strategy aimed at enhancing execution across the company."

The earnings report included diluted GAAP earnings per share of $0.30, with adjusted EPS standing at $0.22. Following these strong results, Avantor has raised its guidance for fiscal year 2026, providing an optimistic outlook for continued organic revenue growth and improved adjusted earnings.

Breakdown by Segments

The performance of Avantor's segments during the third quarter was equally promising, with VWR Distribution Services generating $1.234 billion in net sales, reflecting a growth rate of 5.0%, while Bioscience and Medtech Products reached $464.5 million, marking a 3.5% increase. This indicates a robust recovery path for Bioscience and a solid growth trajectory for VWR, which outperformed expectations with organic growth of 5.8%.

Despite the progress, adjusted operating income for VWR decreased from $132 million to $119 million primarily due to higher selling, general, and administrative expenses. However, adjusted operating income margins remained stable at 9.7%.

Financial Health and Cash Flow

As of September 30, 2026, Avantor's financial condition showed a healthy balance sheet, with total debt at $3.699 billion against $464.3 million in cash reserves. The GAAP net leverage ratio stood at 9.6x, while adjusted net leverage was considerably lower at 3.1x, indicating a strong capacity for debt management.

Operating cash flow reached $195.1 million for the quarter, resulting in free cash flow of $156.2 million, further supporting the company’s intentions to bolster its financial foundations.

Updated Guidance for Fiscal 2026

Anticipating continued growth, Avantor updated its guidance for fiscal year 2026, predicting an organic revenue growth range of +0.75% to +1.25% and adjusted EBITDA margin expectations between 14.8% and 15.3%. These projections underscore the company’s commitment to enhancing profitability and cash flow generation.

Closing Remarks

Avantor’s third-quarter performance and its optimistic outlook reflect a company that is successfully navigating through recovery and growth phases. With strategic focus, a strong product line, and talented workforce, Avantor is well-positioned for future success. Their upcoming conference call will further discuss these results and provide insights into the company’s ongoing initiatives.

For the latest updates and insights about Avantor, visit corporate.avantorsciences.com and follow them on social media platforms.